2. Search Result
Search Result
Results for "

MI/R rabbits model

" in MedChemExpress (MCE) Product Catalog:

7007

Inhibitors & Agonists

8

Screening Libraries

73

Fluorescent Dye

228

Biochemical Assay Reagents

558

Peptides

4

MCE Kits

160

Inhibitory Antibodies

658

Natural
Products

802

Recombinant Proteins

344

Isotope-Labeled Compounds

134

Antibodies

92

Click Chemistry

267

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-136360
    MI-3454
    2 Publications Verification

    		 Epigenetic Reader Domain Cancer
    MI-3454 is an orally active, highly potent and selective menin-MLL1 interaction inhibitor with an IC50 of 0.51 nM. MI-3454 inhibits proliferation, induces differentiation and complete remission or regression of leukemia in mouse models of MLL1-rearranged or NPM1-mutated leukemia through downregulation of key genes involved in leukemogenesis .
    MI-3454
  • HY-150737
    MI-1851

    		SARS-CoV Infection
    MI-1851 is a potent furin inhibitor. MI-1851 prevents the proteolytic processing of the S protein of SARS-CoV-2 by endogenous flavoprotease in HEK293 cells. MI-185 has antiviral activity .
    MI-1851
  • HY-136688
    MI-389

    		PROTACs Cancer
    MI-389 is a PROTAC translation termination factor GSPT1 degrader. MI-389 disrupts a target that is a shared dependency in different AML and ALL cell lines, and that MI-389 action is dependent on the CRL4 CRBN E3 ligase .
    MI-389
  • HY-125858B
    (S,R,S)-MI-1061

    		Drug-Linker Conjugates for ADC MDM-2/p53 Others
    (S,R,S)-MI-1061 is the isomer of MI-1061(HY-125858). (S,R,S)-MI-1061 can used to synthesize Antibody-Drug Conjugates (ADCs). MI-1061 is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC50=4.4 nM; Ki=0.16 nM). MI-1061 potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .
    (S,R,S)-MI-1061
  • HY-133760
    MI-888

    		MDM-2/p53 Cancer
    MI-888 is an orally active MDM2 inhibitor with a Ki of 0.44 nM. MI-888 can inhibit the MDM2-p53 interaction. MI-888 has favorable pharmacokinetic properties and anti-tumor activity .
    MI-888
  • HY-130272
    Anti-MI/R injury agent 1

    		Others Cardiovascular Disease
    Anti-MI/R injury agent 1 (compound 18), a Panaxatriol derivative, is an orally active, potent anti-myocardial ischemia/reperfusion (anti-MI/R) injury agent. Anti-MI/R injury agent 1 enhances oxygen-glucose deprivation and reperfusion (OGD/R)-induced cardiomyocyte injury cell viability. Anti-MI/R injury agent 1 can markedly reduce myocardial infarction size, decrease circulating cardiac troponin I (cTnI) leakage, and alleviate cardiac tissue damage in the rats .
    Anti-MI/R injury agent 1
  • HY-16634
    MI-888 TFA

    		MDM-2/p53 Cancer
    MI-888 (TFA) is an orally active MDM2-p53 interaction inhibitor with a Ki of 0.44 nM. MI-888 (TFA) can achieve rapid, complete, and sustained tumor regression in a xenograft mouse model of cancer .
    MI-888 TFA
  • HY-173033
    MI-883

    		Constitutive Androstane Receptor Cytochrome P450 Metabolic Disease
    MI-883 is the orally active agonist for Constitutive Androstane Receptor (CAR, EC50=73 nM) and the antagonist for Pregnane X Receptor (PXR, IC50=0.1 μM). MI-883 stimulates CAR LBD assembly (EC50=0.38 µM) and CAR3 variant activation (EC50=0.074 µM), induces CYP2B6 mRNA expression in HepaRG and primary human hepatocytes. MI-883 inhibits basal PXR activity IC50=2.03 µM) in transiently transfected HepG2 cells, blocks CYP3A4 mRNA expression in HepG2. MI-883 regulates cholesterol metabolism and bile acid excretion, improves hypercholesterolemia in mouse models .
    MI-883
  • HY-163676
    MI-217

    		Sirtuin Apoptosis Cancer
    MI-217 is a potent SIRT3 inhibitor. MI-217 induces MDA-MB-231 apoptosis. MI-217 can be used in the study of breast cancer .
    MI-217
  • HY-P2357
    MI-1544

    		GnRH Receptor Metabolic Disease
    MI-1544 is a powerful GnRH antagonist. MI-1544 induces inhibitory effects on the pituitary LH release and on gonads. MI-1544 can be used for the research of antifertility effect .
    MI-1544
  • HY-134921
    MI-nc dihydrochloride

    		Epigenetic Reader Domain Cancer
    MI-nc dihydrochloride is a weak inhibitor of the Menin-MLL fusion protein interaction with an IC50 of 193 μM. MI-nc dihydrochloride can be used as a negative control compound of MI-2 .
    MI-nc dihydrochloride
  • HY-143218
    TPE-MI
    3 Publications Verification

    Tetraphenylethene maleiMIde

    		 Huntingtin Parasite Neurological Disease
    TPE-MI (Tetraphenylethene maleimide) is a thiol probe for measuring unfolded protein load and proteostasis in cells. TPE-MI can report imbalances in proteostasis in induced pluripotent stem cell models of Huntington disease, as well as cells transfected with mutant Huntington exon 1 before the formation of visible aggregates. TPE-MI also detects protein damage following dihydroartemisinin research of the malaria parasitesPlasmodium falciparum .
    TPE-MI
  • HY-19319
    MI-136

    		Epigenetic Reader Domain Androgen Receptor Apoptosis Cancer
    MI-136 is an inhibitor of the menin-MLL protein-protein interaction (PPI), with an IC50 of 31 nM and a Kd of 23.6 nM. MI-136 shows to block AR signaling and has the potential for the study in castration-resistant tumors .
    MI-136
  • HY-110264
    MI-192

    		HDAC Apoptosis Neurological Disease Cancer
    MI-192 is a selective HDAC2 and HDAC3 inhibitor with IC50s of 30 nM and 16 nM, respectively. MI-192 is more selective for HDAC2/3 than other HDAC isomers.MI-192 induces myeloid leukaemic cells apoptosis. Anticaner and neuroprotective activities .
    MI-192
  • HY-117365
    MI-1481

    		Epigenetic Reader Domain Cancer
    MI-1481 is a highly potent inhibitor of the Menin-MLL1 interaction with IC50 of 3.6 nM. MI-1481 markedly reduces cell growth of murine bone marrow cells transformed and inhibits leukemia progression .
    MI-1481
  • HY-18331
    MI-219

    		MDM-2/p53 Cancer
    MI-219 is an antagonist for MDM2 with a Ki of 13.3 μM. MI-219 inhibits the MDM2-p53 interaction, inhibits thus the proliferation of FSCCL cells, with an IC50 of 2.5 μM .
    MI-219
  • HY-133754
    MI-1063

    		MDM-2/p53 Ligands for Target Protein for PROTAC Cancer
    MI-1063 is an inhibitor for DMD-2, that blocks the MDM2-p53 interaction, and activates the tumor suppressor function of p53. MI-1063 inhibits the growth of cancer cell RS4-11 and MV4-11 with IC50 of 179 nM and 93 nM. MI-1063 can be used as target protein ligand in synthesis of PROTAC degrader MD-265 (HY-169327) .
    MI-1063
  • HY-17493
    MI-773
    4 Publications Verification

    		 MDM-2/p53 E1/E2/E3 Enzyme Cancer
    MI-773 is a potent MDM2-p53 protein‐protein interaction (PPI) inhibitor with high binding affinity against MDM2 (Kd=8.2 nM). MI-773 has antitumor activity .
    MI-773
  • HY-19810
    MI-538
    3 Publications Verification

    		 Epigenetic Reader Domain Cancer
    MI-538 is an inhibitor of the interaction between menin and MLL fusion proteins with an IC50 of 21 nM.
    MI-538
  • HY-111937
    MI-1

    		Epigenetic Reader Domain Cancer
    MI-1 inhibits Menin-MLL interaction with an IC50 of 1.9 μM .
    MI-1
  • HY-16925
    MI-503
    5+ Cited Publications

    		 Epigenetic Reader Domain Cancer
    MI-503 is a highly potent and orally bioavailable small molecule inhibitor of the menin-mLL interaction.
    MI-503
  • HY-19809
    MI-463
    1 Publications Verification

    		 Epigenetic Reader Domain Cancer
    MI-463 is a highly potent and orally bioavailable small molecule inhibitor of the menin-mLL interaction.
    MI-463
  • HY-108350
    MI-2-2

    		Epigenetic Reader Domain Cancer
    MI-2-2 is a potent menin-MLL inhibitor. MI-2-2 binds to menin with low nanomolar affinity (Kd=22nM) and very effectively disrupts the bivalent protein-protein interaction between menin and MLL. MI-2-2 has specific and very pronounced activity in MLL leukemia cells, including inhibition of cell proliferation, down-regulation of Hoxa9 expression, and differentiation .
    MI-2-2
  • HY-161902
    MI-1904

    		Ser/Thr Protease Influenza Virus SARS-CoV Infection
    MI-1904 is the inhibitor for matriptase/TMPRSS2, that exhibits antiviral activity against influenza virus H1N1 and H9N2. MI-1904 blocks the cleavage of glycoproteins on the viral surface, prevents the virus from binding to host cell receptors, and thus inhibits the entry and replication of the virus .
    MI-1904
  • HY-18330
    MI 63

    		MDM-2/p53 Cancer
    MI 63 is an activator for p53, by targeting the MDM2 (Ki is 3 nM). MI 63 inhibits the proliferation of embryonic and alveolar rhabdomyosarcoma (ERMS and ARMS) cells (IC50 is 0.58 μM in RH36 cells), and induces apoptosis in ERMS and ARMS .
    MI 63
  • HY-125858
    MI-1061
    1 Publications Verification

    		 MDM-2/p53 E1/E2/E3 Enzyme Apoptosis Cancer
    MI-1061 is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC50=4.4 nM; Ki=0.16 nM). MI-1061 potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .
    MI-1061
  • HY-D1781
    NTPAN-MI

    		Fluorescent Dye Others
    NTPAN-MI is a fluorescent probe. NTPAN-MI is selectively activated upon labeling unfolded proteins with exposed thiols, thereby reporting on the extent of proteostasis .
    NTPAN-MI
  • HY-18986
    SAR405838
    2 Publications Verification

    MI-77301

    		 MDM-2/p53 E1/E2/E3 Enzyme Apoptosis Cancer
    SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective MDM2-p53 interaction inhibitor. SAR405838 binds to MDM2 with a Ki of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity .
    SAR405838
  • HY-169504
    MI-4F

    		Drug Derivative Cancer
    MI-4F is mesoionic compound that exhibits potent anticancer activity against multiple cancer cell lines and in vivo .
    MI-4F
  • HY-125858A
    MI-1061 TFA
    1 Publications Verification

    		 MDM-2/p53 E1/E2/E3 Enzyme Apoptosis Cancer
    MI-1061 TFA is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC50=4.4 nM; Ki=0.16 nM). MI-1061 TFA potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .
    MI-1061 TFA
  • HY-12276
    MALT1 inhibitor MI-2
    5+ Cited Publications

    		 MALT1 Cancer
    MALT1 inhibitor MI-2 is a MALT1 inhibitor (IC50=5.84 μM). MALT1 inhibitor MI-2 binds directly to MALT1, irreversibly suppresses protease function and is accompanied by NF-κB reporter activity suppression, c-REL nuclear localization inhibition, and NF-κB target gene downregulation. MALT1 inhibitor MI-2 shows nontoxic to animals .
    MALT1 inhibitor MI-2
  • HY-110248
    MI 14

    		PI4K HCV Infection
    MI 14 is a selective PI4KIIIβ inhibitor with IC50s of 54 nM, >100 μM, >100 μM for PI4KIIIβ, PI4KIIIα, PI4KIIα, respectively. MI 14 has antiviral activity against HCV 1b, CVB3, HRVM, HVC 2a .
    MI 14
  • HY-15222
    Menin-MLL inhibitor MI-2
    3 Publications Verification

    		 Epigenetic Reader Domain Apoptosis Cancer
    Menin-MLL inhibitor MI-2 is a Menin-MLL interaction inhibitor with IC50 of 446±28 nM.
    Menin-MLL inhibitor MI-2
  • HY-162538
    LC-MI-3

    		NF-κB IRAK PROTACs Inflammation/Immunology
    LC-MI-3 is an orally active and potent interleukin-1 receptor-associated kinase 4 (IRAK4) PROTAC degrader, with a DC50 of 47.3 nM. LC-MI-3 effectively inhibits the activation of downstream NF-κB signaling. LC-MI-3 can be used for the research of acute and chronic inflammatory skin. (Blue: VHL ligand, Black: linker, Pink: CRBN ligand (HY-14658)) .
    LC-MI-3
  • HY-155079A
    (R)-DZD1516

    		EGFR Others
    (R)-DZD1516 is the R enantiomer of DZD1516 (HY-155079). DZD1516 is a potent and selective HER2 inhibitor .
    (R)-DZD1516
  • HY-B0027
    Valnemulin hydrochloride
    2 Publications Verification

    		 Antibiotic Bacterial Infection Metabolic Disease
    Valnemulin hydrochloride is an orally effective truncated pleurotin antibiotic that inhibits protein synthesis in bacteria by binding to peptidyl transferase in the 50s ribosome subunit. Valnemulin hydrochloride effectively eliminates Mycobacterium bovis in the lungs in an experimental bovine model of Mycoplasma bovis infection. Valnemulin hydrochloride can reduce the mortality of epidemic rabbit enteropathy and has no adverse effect on the growth performance of rabbits .
    Valnemulin hydrochloride
  • HY-15223
    MI-3
    1 Publications Verification

    Menin-MLL inhibitor 3

    		 Epigenetic Reader Domain Apoptosis Cancer
    MI-3 (Menin-MLL inhibitor 3) is a potent and high affinity menin-MLL inhibitor with an IC50 of 648 nM and a Kd of 201 nM .
    MI-3
  • HY-18986S
    SAR405838-d10

    MI-77301-d10

    		 Isotope-Labeled Compounds Cancer
    SAR405838-d10 (MI-77301-d10) is the deuterium labeled SAR405838 (HY-18986). SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective MDM2-p53 interaction inhibitor. SAR405838 binds to MDM2 with a Ki of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity .
    SAR405838-d10
  • HY-119035
    R-75317

    		Platelet-activating Factor Receptor (PAFR) Inflammation/Immunology
    R-75317 is a specific platelet-activating factor (PAF) antagonist. R-75317 can prevent the decline in creatinine clearance (Ccr) in a rat model of glomerulonephritis induced by the injection of antibodies extracted from rabbits against rat glomerular basement membrane (GBM) antigens, delay the onset of proteinuria, and improve glomerular hypertrophy, mesangial matrix proliferation, and interstitial fibrosis. R-75317 may be useful in the study of glomerulonephritis .
    R-75317
  • HY-19606
    Cytogenin

    Antibiotic MI 43-37F11

    		 Interleukin Related NO Synthase Metabolic Disease Inflammation/Immunology Cancer
    Cytogenin (Antibiotic MI 43-37F11) is an orally active antineoplastic antibiotic. Cytogenin regulates the inflammatory cytokine, reduces the levels of iNOS, NO and IL-6 in mouse macrophages, and exhibits antidiabetic efficacy in mice. Cytogenin inhibits growth of Ehrlich ascites tumor in mouse model .
    Cytogenin
  • HY-168382
    5R(6S)-EET

    		Prostaglandin Receptor Endogenous Metabolite Others
    5R(6S)-EET is the metabolite of Arachidonic acid (HY-109590). 5R(6S)-EET activates the synthesis of endogenous prostaglandin (PGE2), which inhibits the Na + absorption, increases the intracellular Ca 2+, and promotes the depolarization of transmembrane voltage. 5R(6S)-EET exhibits stereoselectivity with less effectness than 5S(6R)-EET (HY-168382A) .
    5R(6S)-EET
  • HY-168382A
    5S(6R)-EET

    		Prostaglandin Receptor Endogenous Metabolite Others
    5S(6R)-EET is the metabolite of Arachidonic acid (HY-109590). 5S(6R)-EET activates the synthesis of endogenous prostaglandin (PGE2), which inhibits the Na + absorption, increases the intracellular Ca 2+, and promotes the depolarization of transmembrane voltage. 5S(6R)-EET is more active than 5R(6S)-EET (HY-168382) .
    5S(6R)-EET
  • HY-161282
    hCAII-IN-10

    		Carbonic Anhydrase Neurological Disease Cancer
    hCAII-IN-10 (compound 11d) is hCA II inhibitor with the IC50s of 14 nM and 29.2 μM for hCA II and hCA I, respectively. hCAII-IN-10 inhibits cell growth against HT-29 cells with the IC50 of 74 μM. hCAII-IN-10 shows strongly lowered intraocular pressure in the glaucomatous rabbit eye model .
    hCAII-IN-10
  • HY-B0102C
    (R)-Fluoxetine hydrochloride

    		Serotonin Transporter Neurological Disease
    (R)-Fluoxetine hydrochloride, an antidepressant, is serotonin reuptake inhibitor (SSRI). (R)-Fluoxetine hydrochloride has modest affinity at the 5-HT2A and 5-HT2C receptors .
    (R)-Fluoxetine hydrochloride
  • HY-13956C
    (R)-Pioglitazone

    (R)-U 72107

    		 PPAR Neurological Disease
    (R)-Pioglitazone ((+)-pioglitazone) is the R enantiomer of Pioglitazone (HY-13956). (R)-Pioglitazone is an orally active and selective peroxisome proliferator-activated receptor (PPARγ) agonist with high affinity binding to the PPARγ ligand-binding domain. (R)-Pioglitazone can be used for the research of Alzheimer's disease .
    (R)-Pioglitazone
  • HY-171037
    Prostaglandin Bx

    PGBx

    		 Mitochondrial Metabolism Neurological Disease
    Prostaglandin Bx (PGBx) is an oligomer of PGB1 and 15-keto-PGB, which exhibits mitochondrial protective efficacy. Prostaglandin Bx promotes the neurological recovery in rabbits ischemic spinal cord injury model, and maintains the integrity of the gastric mucosa through inhibition of gastric acid secretion in rat gastric ulcer model .
    Prostaglandin Bx
  • HY-106841
    Draflazine

    R-75231; R88021

    		 Adenosine Receptor Inflammation/Immunology
    Draflazine (R-75231) is a ENT1 inhibitor. Draflazine (R-75231) completely reverses the hypersensitivity in the complete Freund’s adjuvant (CFA) model of mechanical hyperalgesia and the carrageenan inflammation model of thermal and mechanical hyperalgesia .
    Draflazine
  • HY-105919
    Naroparcil

    		Factor Xa Cardiovascular Disease
    Naroparcil is an orally active antithrombotic agent. Naroparcil exhibits antithrombotic effects in rabbit Wessler stasis model with EC50s of 21.9 mg/kg and 36.0 mg/kg after respectively intravenous injection and oral administration .
    Naroparcil
  • HY-P5631
    Rabbit neutrophil peptide 3b

    		Bacterial Infection
    Rabbit neutrophil peptide 3b is an antimicrobial peptide derived from rabbit peritoneal neutrophils .
    Rabbit neutrophil peptide 3b
  • HY-136165
    (S,R,S)-AHPC-PEG3-propionic acid

    		E3 Ligase Ligand-Linker Conjugates Cancer
    (S,R,S)-AHPC-PEG3-propionic acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology .
    (S,R,S)-AHPC-PEG3-propionic acid

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: